The Global Axial Spondyloarthritis Market is undergoing a remarkable surge, projected to reach USD 4.95 billion by 2028, with a compelling CAGR of 14.8% from ... Therapies such as anti-janus kinase, ...

Researchers report results of the first-in-human phase 1 clinical trials of a novel immunotherapy approach for solid tumors ...

In recent years, the evolution of biologic therapies for severe asthma has paralleled advancements in other chronic ...

Researchers at Moffitt Cancer Center focused on a form of cell death called necroptosis. Previously thought to help the ...

Biologic therapies are revolutionising severe asthma management, showcasing potential for remission, but cost and equitable ...

FDA Project Team supports the company's proposed Phase 3 trial strategy, including overall trial design, target patient population, treatment schedule, and primary endpoint Final Protocol submission ...

Protagonist' or the 'Company') today announced the selection of PN-881, a potential best-in-class oral peptide interleukin-17 (IL-17) antagonist ... Details The dial-in numbers for Protagonist's ...

Interleukin-1 receptor-associated kinase 4 is critical in the modulation of inflammatory responses through Toll-like receptor and IL-1R signaling.

The US Food and Drug Administration has approved bimekizumab, a humanized interleukin (IL)-17A and IL-17F antagonist, for the ...

A trio of abstracts presented at ACR Convergence 2024, the annual meeting of the American College of Rheumatology, bear out the benefits of bimekizumab (Bimzelx; UCB Pharma) for use against active ...

In mice, dampening the activity of area postrema neurons diminished cancer-induced muscle and fat loss and increased lifespan ...

A new study published in the journal of Respiratory Medicine showed that patients with type 2 inflammation and chronic ...